Agenda for Day One - Tuesday November 17, 2026 - EST
This session opens with a look at the macro forces reshaping the industry and how leading life sciences organizations are responding. We'll then take you inside Anaplan's new GTN application, purpose-built with industry best practices, faster to implement, and designed to lower total cost of ownership. A live demo will show how Anaplan's AI capabilities surface insights in moments rather than days.
Key highlights include:
- What's changed in the GTN landscape over the past year, and where the market is heading
- A live demo of Anaplan's new GTN application, including customer-level forecasting across rebates, chargebacks, distributor agreements, and government price types
- How Anaplan AI accelerates scenario analysis, variance explanation, and forecast insight
- Why GTN is the ideal launching point for transformation, and how mature customers extend into connected pre-deal, post-deal, demand, and financial planning
Walk away with a clear picture of what's possible today and a roadmap for turning GTN into the catalyst for enterprise-wide change.
- Scott DeKoster - RVP, Life Sciences, Anaplan
- Nicholai Anderson-Peña - Solutions Consulting, Life Sciences, Anaplan
- Tara Rockers - GM Strategy, Life Sciences, Anaplan
- Prakash Chainani - Senior Vice President – Finance, HR and IT, Lifestar Pharma LLC (a Mankind Group Company)
- Translate complex Gross-to-Net analytics and AI-enabled insights into clear narratives for executive and cross-functional audiences
- Use AI-powered presentation approaches to communicate financial data and technical concepts as clear, actionable business insights that can inform strategic decision-making
- Explore frameworks that can support greater predictability in Gross-to-Net provisions and accruals under ASC 606, including the documentation of significant estimates and considerations for an enabled, end-to-end approach
CPE Credits Available: 1.2
- Jenisha Malhotra - Senior Manager, Deloitte & Touche LLP
- Michael Kirk - Senior Manager, Deloitte & Touche LLP
- IRA implementation, financial implications, and strategies to adapt
- MFP program implementation: accounting treatment, revenue recognition adjustments, quarterly close processes, reconciliation methodologies, and audit documentation requirements
- Medicare Part D redesign
- Medicaid best price considerations
- MFN updates
- CMS international reference pricing initiatives (GENEROUS/GUARD/GLOBE)
- 340B reform impacts
- Impact of tariffs
- Examine net revenue implications through real-world case studies demonstrating the financial impact of key policy and regulatory updates
CPE Credits Available: 1.2
- Walt Worsham - Managing Director, IntegriChain
- Master price protection mechanisms and contractual triggers across commercial plans, Medicaid (best price, URA), Medicare (Part D, coverage gap), and institutional channels (GPOs, 340B), with practical frameworks for managing obligations and minimizing revenue risk
- Implement advanced GTN accrual methodologies and revenue recognition strategies for forecasting price protection liabilities, modeling inflation adjustments and regulatory price increases, while maintaining ASC 606 compliance
- Build financial controls for tracking and validating claims across payer types, ensuring provision accuracy, streamlining true-up processes and resolving cross-channel conflicts
- Develop audit-ready documentation practices and compliance strategies for price protection calculations across payer channels, ensuring defensible assumptions and regulatory preparedness
CPE Credits Available: 1.2
- Hilary Sherman - Independent, Independent
- Darpan Jhaveri - Senior Director - US Revenue and Inventory Accounting, Insmed Incorporated
- Felecia Manning - Senior Director, Pricing and Government Programs, Market Access, United Therapeutics Corporation
- Jennifer English - Value & Access Chief of Staff, Head of US Price & Value Optimization, Ipsen
This session explores the end-to-end GTN story and the key activities that influence net price realization. As manufacturers seek greater visibility to support profitable contracting strategies and minimize revenue leakage, understanding how information flows across functions becomes increasingly important. Topics include forecasting, accruals, rebate processing, dispute resolution, reserve releases, and financial reporting. Attendees will see how OpenPharma connects Market Access and Finance to provide a comprehensive view of the GTN lifecycle and enables manufacturers to better understand the drivers behind their GTN performance.
- Josh Gingerich - Chief Customer Success Officer, Kernel Solutions
- Marcus Bourget - Customer Success Officer, Kernel Solutions
- Master early-stage asset and launch brand forecasting with proven frameworks for building defensible assumptions and managing stakeholder expectations across uncertain market conditions
- Develop flexible scenario planning and stress-testing capabilities to rapidly adapt forecasts for policy changes (340B reform, IRA implementation, Medicare rebates), incorporating regulatory uncertainty and quantifying financial impacts
- Leverage automation and AI-driven analytics to enhance forecasting accuracy, including predictive modeling, automated variance detection and robust variance analysis methodologies that identify root causes and drive continuous improvement
- Discuss how Finance keeps pace with business changes and adds strategic value by rapidly adapting GTN forecasts to market share gains/losses, product launches and discontinuations and governmental impact on drug pricing, while seamlessly integrating with FP&A and corporate planning cycles to meet strategic targets and enhance shareholder value through proactive scenario planning and cross-functional collaboration
CPE Credits Available: 1.2
- Timothy Bonn - Senior Director, Gross to Net, Breakaway Technologies
- Bal Ram Chopra - Senior Vice President, Finance & Operations, Tethra Biosciences
- Sean McNish - Vice President, Contracts & Pricing, EMD Serono
- Mo Waziri - Head of Pricing, GTN, Allergan Aesthetics, an AbbVie company
- Gain direct insights from auditors on GTN-specific expectations for manufacturers, including documentation standards for rebate accruals, chargeback calculations, Medicaid best price determinations, challenges in estimations of accruals and audit controls, and common GTN compliance gaps that trigger audit findings
- Master best practices for managing auditor relationships throughout GTN audit cycles, from planning rebate provision reviews and fieldwork on revenue recognition to quarter-end closes, provision true-ups and SOX controls specific to gross-to-net calculations
- Understand what auditors prioritize when reviewing GTN work instructions, SOPs for rebate processing, contract interpretation documentation, and control frameworks around price protection mechanisms, with practical guidance on maintaining audit trails for GTN adjustments and supporting evidence for revenue deductions
- Develop proactive approaches to address auditor concerns specific to GTN complexities before they become findings, including effective communication strategies around forecast assumptions, variance explanations for GTN provisions, and relationship management techniques that streamline reviews of complex rebate structures and multi-channel discount programs
CPE Credits Available: 1.2
- Nate Koffel - Senior Manager – Audit & Assurance, Deloitte & Touche LLP
- Prakash Chainani - Senior Vice President – Finance, HR and IT, Lifestar Pharma LLC (a Mankind Group Company)
- Nick Olivares - Director, Revenue Forecasting & GTN, Lundbeck
- Brett Nussbaum - Head of Gross to Net Accounting, Novartis
- Matt Pellegrini - Former Senior Director - Contract Operations N.A., Formerly Teva Pharmaceuticals
- Master data management fundamentals including traceability, accuracy, governance, and quality controls, with strategies for integrating new data sources such as IRA information and leveraging tools for efficient data validation and scrubbing processes
- Navigate emerging record retention requirements for MFP with clarity on compliance obligations, manage the impact on rebates, and address challenges in payer data submission processes while ensuring cross-source reconciliation and data integrity
- Implement data governance frameworks and organizational structures that establish clear ownership, accountability, and quality standards across GTN data sources, with practical approaches for measuring and improving data quality through KPIs and continuous monitoring
CPE Credits Available: 1.0
- Mike McCarthy - Partner, Argano
- Brian Barbash - Partner, Argano
- Explore how companies are rethinking where GTN forecasting, accounting, and contracting functions sit within their organizations, and what's driving the shift toward new structures in today's pharmaceutical landscape
- Review how GTN teams are currently positioned across finance, commercial, and hybrid models, and what factors (such as like company size and portfolio complexity) shape the right fit
- Identify best practices for organizational design, including collaboration models, reporting lines, and governance approaches that help GTN teams stay accurate, compliant, and aligned with broader business goals
CPE Credits Available: 1.0
- Neel Shah - Managing Director, Gross-to-Net, Riparian
- Jeffrey Miller - Vice President, Finance & Corporate Controller, Lannett Company
- Kinneret Klein - Executive Director, Commercial Financial Planning & Analysis, Biocryst
- Angelina Pigna - Senior Director, Pricing, Contracting & Government Programs, Coherus Oncology
